GlassScriptPhysician profile
Stacey Cacchio
NPI 1245447606
$5,182.90
in general payments reported to CMS, 2019-2025
45 companies · $805 in 2025
The $805 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $164 · 2021: $833 · 2022: $891 · 2023: $1,332 · 2024: $912 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,048.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.37 | 2019-2025 | Ubrelvy, Qulipta, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $451.54 | 2021-2025 | |
| Myriad Women'S Health, INC. | $413.68 | 2023 | Myrisk |
| Astellas Pharma US INC | $292.11 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $288.52 | 2019-2025 | |
| Aspira Women'S Health INC | $268.34 | 2021-2024 | Ova1 |
| Hologic Sales and Service, LLC | $230.52 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Myovant Sciences INC. | $183.01 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $180.61 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $180.04 | 2019-2024 | Slynd |
| Gynesonics, INC. | $179.63 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Therapeuticsmd, INC. | $154.47 | 2019-2022 | |
| Daiichi Sankyo INC. | $135.44 | 2020-2024 | Injectafer |
| Agile Therapeutics, INC. | $118.70 | 2021-2024 | Twirla |
| Organon LLC | $109.72 | 2022-2025 | Nexplanon, Jada System |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $94.62 | 2022 | |
| Biogen, INC. | $86.02 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $70.77 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $70.17 | 2021-2024 | Bridion, Gardasil 9, Gardasil |
| Boston Scientific Corporation | $66.75 | 2019 | |
| Minerva Surgical, INC | $64.26 | 2019-2022 | |
| Evofem Biosciences, INC. | $57.72 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $47.13 | 2023-2025 | Exparel, Iovera, Zilretta |
| Mylan Pharmaceuticals INC. | $44.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.00 | 2023 | |
| Coopersurgical, INC. | $40.45 | 2022-2024 | Paragard T 380a |
| Novo Nordisk INC | $38.63 | 2025 | Wegovy |
| Baxter Healthcare | $38.23 | 2024-2025 | Tisseel, Perclot |
| Avion Pharmaceuticals | $38.20 | 2019-2020 | |
| Amgen INC. | $38.18 | 2024-2025 | Evenity, Prolia, Prolia |
| Lupin INC. | $28.49 | 2019-2021 | |
| Ethicon US, LLC | $28.06 | 2023 | Dermabond Prineo, Stratafix |
| Optumhealth Care Solutions, LLC | $27.60 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Allergan, INC. | $24.09 | 2019 | |
| Exact Sciences Corporation | $22.29 | 2025 | Cologuard Collection Kit |
| Vertical Pharmaceuticals, LLC | $20.83 | 2019 | |
| Millicent US INC | $20.24 | 2024 | Intrarosa |
| Ibsa Pharma INC. | $16.87 | 2023 | Tirosint, Licart |
| Alexion Pharmaceuticals, INC. | $15.80 | 2025 | Ultomiris |
| Currax Pharmaceuticals LLC | $14.91 | 2024 | Contrave |
| Amag Pharmaceuticals, INC. | $13.81 | 2020 | |
| Medtronic, INC. | $13.34 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.74 | 2021 | |
| Coloplast Corp | $11.20 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Cacchio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.